One of the makers of the COVID vaccine, Pfizer Inc, has announced plans to purchase Biohaven Pharmaceutical Holding Co. The company revealed their intensions of paying $11.6 billion to tap into the migraine medicine market. The buyout was approved by the boards of both companies. The migraine medicine company’s shares jumped 70% to $141.31 apiece. […]
The post Pfizer Plans to Purchase Biohaven Pharmaceutical Holding Co appeared first on Guardian Liberty Voice.